drugset / Trial / NCT01014468
Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
RandomizedParallel-groupDouble-blindTreatment
Summary
To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.
Timeline
- Start
- 2009-03
- Primary completion
- 2009-11
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |